Elizabeth L. Lockerman
Harvard University · 104 works · 7,504 citations · h-index 17
Top works
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
- Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1
- The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
- Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
- CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF -Mutant Colorectal Cancer through MAPK Pathway Alterations
- Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
- Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer
- EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
- Variation in Mechanisms of Acquired Resistance Among EGFR-Mutant NSCLC Patients With More Than 1 Postresistant Biopsy
- Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM
- Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways
- Abstract 957: The ALK inhibitor LDK378 overcomes crizotinib resistance in non-small cell lung cancer
- Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy.
- Evolution of resistance in ALK-positive patients treated with ALK tyrosine kinase inhibitors (TKIs).